U.S. panel votes against calcitonin salmon bone drug

Posted on March 7th, 2013 by Logan Lafferty

But other panelists said the drugs are an important option for patients who have bad reactions to newer drugs, including bisphosphonate drugs like Fosamax. "We have a whole lot of patients who can't take the other drugs, and I think our patients would be in worse shape without this," said Bart Clark, professor at the Mayo Clinic College of Medicine in Rochester, Minnesota.



Tags: calcitonin, CTV, Dr. Bart Clark, Fosamax, Mayo Clinic College of Medicine, Mayo Clinic Rochester, Pharmacology

You must be logged-in to the site to post a comment.

Contact Us · Privacy Policy